$PRLD

Prelude Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$5.48 ▲7.184%

Last Close

VOLUME

130,087

DAY RANGE

5.2 - 5.79

52 WEEK

3.87 - 43.55

Join Discuss about PRLD with like-minded investors

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Friday, October 8, 2021 Futures Up/Down % Last Dow 42.00 0.12% 34,678 S&P 500 2.50 0.06% 4,392 Nasdaq 0.00 0.00% 14,881 After a week of overnight swings and market volatility, U.S. futures come into Friday’s trading looking flat, with the S&P little changed at 4,390 after a strong session on Thursday was met with a late day pullback, as major averages finished well off their best levels. U.S. futures steady as investors anticipate a key employment report that could offer clues on the Fed’s timeline for reducing bond purchases. Nonfarm payroll data at 8:30 AM with an est. for +500K jobs added, private payrolls est. +455K, manufacturing payrolls +25K and the unemployment rate to fall to 5.1% from 5.2%; average hourly earnings expected to rise +0.4% (vs. last month +0.6%). Equities rose and Treasuries sank on Thursday after Senate leaders pulled the U.S. from the brink of default with a deal for a short-term debt ceiling increase in the amount of $480B to a $28.9 trillion debt limit. However, this could be short lived as the agreement only funds Treasury debt until Dec. 3, meaning Senators will again face a deadline for default. In Asian markets, the Shanghai Index opened for trading after a week long pause to celebrate its Golden Week holiday, rising 24 points to 3,592, the Hang Seng Index gained 136 points to 24,837 and the Nikkei advanced 370 points (1.34%) to 28,048. In Europe, the German DAX is down a few points at 15,235, while the FTSE 100 is up a few at 7,085. Oil prices are higher, heading for its seventh weekly gain with WTI crude nearing $80 Market Closing Prices Yesterday The S&P 500 Index gained 36.21 points, or 0.83%, to 4,399.76 The Dow Jones Industrial Average rose 337.95 points, or 0.98%, to 34,754.94 The Nasdaq Composite surged 152.10 points, or 1.05%, to 14,654.02 The Russell 2000 Index advanced 35.14 points, or 1.59% to 2,250.09 Events Calendar for Today 8:30 AM ET Non-Farm Payrolls for September…est. +500K 8:30 AM ET Private Payrolls for September…est. +455K 8:30 AM ET Manufacturing Payrolls for September…est. +25K 8:30 AM ET Unemployment Rate for September…est. 5.1% 8:30 AM ET Average Hourly Earnings for September…est. +0.4% 10:00 AM ET Wholesale Inventories MoM for Aug 1:00 PM EST Baker Hughes Weekly rig count data Macro Up/Down Last Nymex 0.58 78.86 Brent 0.65 82.60 Gold 0.90 1,762.00 EUR/USD 0.0014 1.1563 JPY/USD 0.23 111.82 10-Year Note +0.021 1.593% World News The U.S. Senate on Thursday approved legislation to temporarily raise the federal government’s $28.4 trillion debt limit and avoid the risk of a historic default this month, but it put off until early December a decision on a longer-lasting remedy. German Aug Trade Balance smaller surplus: +€13.0b vs +€15.8b consensus; German August Exports lower down -1.2% vs +0.5% consensus and German Aug Imports higher rising +3.5% vs 1.8% consensus Sector News Breakdown Consumer Home Depot ($HD) and Lowe’s ($LOW) both downgraded to Hold from Buy at Loop Capital Tesla ($TSLA) CEO Elon Musk confirmed that the car maker is moving its headquarters from Fremont, California to Austin, Texas, where the company has been constructing a new factory for a little over a year. CEO Musk also said a global shortage of chips and ships is the only thing standing in the way of the company maintaining sales growth in excess of 50% Oatly Group ($OTLY) upgraded to Overweight from Neutral with a $21 price target Drive Shack ($DS) reports prelim Q3 revs of $75M vs. est. $76.74M Scientific Games ($SGMS) wins 10-year Vermont lottery systems contract; company’s advanced platforms and game services will modernize lottery play and maximize revenues for programs in green mountain state Thor Industries ($THO) increases regular quarterly dividend 5% to 43c per share Energy, Industrials and Materials Dow Transports finished the day down -0.25% just above the 14,500 level, but slipping below its 50-day MA at 14,515 B. Hunt ($JBHT) downgraded to Underweight on relative valuation at JPMorgan Union Pacific ($UNP) upgraded to Overweight from Neutral with a price target of $247, up from $234 at JPMorgan on recent selloff Sundial Growers Inc. ($SNDL) announced it will acquire liquor and pot retailer Alcanna in an all-stock deal with a total consideration of about C$346M Financials Pzena Investment Management Inc. ($PZN) prelim AUM as of Sept 30 of $50.8 bln Chubb ($CB) announced a definitive agreement to acquire the life and non-life insurance companies that house the personal accident, supplemental health and life insurance business of Cigna (CI) in seven Asia-Pacific, or APAC, markets for $5.75B in cash Healthcare Accolade Inc. ($ACCD) Q2 revs $73.3M vs. est. $70.4M; Q2 adj Ebitda loss (-$19.4M) vs. est. loss (-$21.9m); sees FY revs $303M-$307M, from prior view $300M-$305M (est. $303.4M); guides Q3 adj Ebitda loss $21.5M-$24.5M vs. est. loss $20.2M, but Q3 revs above views Quidel ($QDEL) guides Q3 revs $505M-$510M vs. est. $186.3M; says covid-19 revenues for Q3 of 2021 expected to be about $406M, compared with $375.7M YoY Allogene Therapeutics ($ALLO) shares fall over 35% after reporting the FDA put a clinical hold of Allocar T trials based on a single patient case in alpha2 trial; believes data from alpha trials demonstrates a favorable clinical profile of allo-501a Apollo EndoSurgery ($APEN) sees 3Q revs $16-16.4Mm vs est. $14.4Mm; sees 3Q net loss $6.1-7.3Mm vs est. net loss $8.3Mm BeiGene’s ($BGNE) BRUKINSA (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior therapy or in first line treatment for patients unsuitable for chemo-immunotherapy. Mirati Therapeutics ($MRTX) to collaborate with Sanofi ($SNY) on phase 1/2 study evaluating combination of adagrasib with a SHP2 inhibitor in KRAS g12c-mutated lung cancer Nkarta ($NKTX) provided updates on its NKX019 and NKX101 clinical development programs saying patients have been dosed in the international phase 1 trial of NKX019 in advanced B-cell malignancies IsoPlexis (ISO)333M share IPO priced at $15.00 Pyxis Oncology ($PYXS)5M share IPO priced at $16.00 Prelude Therapeutics ($PRLD) shares fall after announces presentation of encouraging data from multiple programs at the AACR-NCI-EORTC virtual international conference on molecular targets and cancer therapeutics Relay Therapeutics ($RLAY) announces interim clinical data for RLY-4008, in a first-in-human trial in patients with FGFR2-altered cholangiocarcinoma and multiple other solid tumors Technology, Media & Telecom VMware ($VMW) authorized new stock buyback program for up to $2B Samsung Electronics Co Ltd ($SSNLF) said Q3 operating profit likely jumped 28% to its highest in three years, helped by rising memory chip prices and brisk sales of its new foldable smartphones; estimated July-September profit at 15.8 trillion won ($13.3 billion) vs. est. of 16.1 trillion won. ChipMOS (IMOS) reports Q3 revenues rose 25.9% on a Y/Y basis to $257.2M (+2.6% Q/Q) vs. a consensus of $262.90M. Taiwan Semiconductor Manufacturing Co.’s ($TSM) September revenue was up 19.7% Y/Y to NT$152.69B or about $5.44B. AU Optronics ($AUOTY) reports September revenue rose 26.5% Y/Y to NT$33.0B (+0.9% M/M); Q3 revenues rose 35.3% Y/Y NT$99.05B Oracle ($ORCL), Telecom Italia, and Noovle, TIM Group’s cloud company, have signed a collaboration agreement to offer multi-cloud services for enterprises and the public sector organizations in Italy. Sirius XM ($SIRI) downgraded to Neutral from Overweight with a price target of $7, down from $8 at JPMorgan

109 Replies 15 👍 9 🔥

SO
@soheil.n #StockTraders.NET
recently

anyone seen the $PRLD chart

119 Replies 13 👍 13 🔥

Key Metrics

Market Cap

263.28 M

Beta

0

Avg. Volume

222.48 K

Shares Outstanding

47.70 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-11

Next Dividend Date

Company Information

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Website:

HQ: ,

Related News